Premium
Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis
Author(s) -
Williams Mark E,
Weinblatt Michael,
Rosa Robert M,
Griffin Victoria L,
Goldlust M Barry,
Shang Shaw F,
Harrison Lester I,
Brown Robert S
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.65
Subject(s) - hemodialysis , medicine , dialysis , dosing , pharmacokinetics , urology , chronic renal failure , metabolite , gastroenterology
A 1500 mg dose of salsalate (SSA) was given to five patients undergoing chronic hemodialysis on an interdialytic day and again before dialysis. Compared with control subjects, patients undergoing dialysis had a lower peak plasma SSA level (17 ± 3 vs. 45 ± 2 μg/ml; P < 0.01) that occurred slightly later. In contrast, plasma salicylic acid (SA), the active SSA metabolite, had a similar but later peak level that remained substantially higher. Therefore, the AUC for SA was increased by 50% and the SA t ½ was prolonged in the patients receiving dialysis (8.1 ± 0.7 vs. 3.8 ± 0.2 hours; P < 0.01). During a single treatment, dialysis clearance reduced plasma SA levels, removed 18% of total body SA, and returned the SA t ½ to nearly normal. Because the elimination of SA is impaired in patients undergoing dialysis, the interdialytic SSA dosage should be reduced. Hemodialysis improves SA kinetics and may be followed by a normal SSA replacement dose. However, periodic monitoring of plasma SA levels is recommended when SSA dosing is begun in patients receiving dialysis. Clinical Pharmacology and Therapeutics (1986) 39, 420–424; doi: 10.1038/clpt.1986.65